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Abstract (249 words) 
Objectives: Data on adult IgA vasculitis (IgAV) are scarce. This survey was 
designed to better define clinical spectrum and efficacy of treatments in this 
population. 
Methods: We analyzed data from 260 patients with IgAV included in a French 
multicenter retrospective survey.  
Results: Mean age at diagnosis was 50.1±18 years, and 63% were male. Baseline 
manifestations included purpura (100%), arthralgia (62%), glomerulonephritis (70%) 
or gastro-intestinal involvement (53%). Thirty percent showed at baseline renal 
failure. In univariate analysis, response was 80% (n=64/80) in patients treated with 
corticosteroids (CS) alone compared to 77% (n=23/30) in patients treated with 
cyclophosphamide (CYC) and 10/17 (59%) treated with colchicine (P=0.17).  
Multivariable analysis showed that patients treated with CS or CS plus CYC were 
more effective than colchicine in achieving response using different statistical 
analysis: logistic regression model [OR (95% CI) 3.68 (1.10-12.33), P=0.03], inverse 
probability weighting on Propensity Score (PS) [OR 3.75 (1.28-10.99), P=0.02]. 
Efficacy of CS plus CYC versus CS were discordant according to the method used. 
The use of multivariable logistic regression model [OR 0.88 (0.29-2.67), P=0.82] did 
not demonstrate difference, in contrast, inverse probability weighting on PS with [OR 
1.79 (1.00-3.20), P=0.049] showed that CS plus CYC were more effective. 
Conclusion: This series constitutes the largest series reported so far in the literature 
of adults IgAV. It provides data on clinical and histological presentation and 
therapeutic efficacy, suggesting that CS alone appears to be a reasonable first-line 
therapy in patients with IgAV, while the benefit of adding CYC to CS remains 
uncertain.  
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Introduction  
 Immunoglobulin A (IgA) vasculitis, formerly called Henoch–Schönlein purpura, 
is an immune complex small vessel vasculitis with IgA1-dominant immune deposits 
(1). IgA vasculitis (IgAV) is the most common systemic vasculitis in childhood with an 
annual incidence of 3 to 26 per 100 000 children (2). In adults, the disease is less 
common with an annual incidence of 0.1 to 1.8 per 100 000 individuals (3, 4),(5). 
IgAV frequently involves the skin, the gastrointestinal tract, the joints with arthralgias 
and/or arthritis, and the kidneys (6). Gastrointestinal tract and renal involvements 
represent the main causes of morbidity and mortality in adults. In a large study of 250 
IgAV in adults, 11% of patients reached end-stage renal disease (ESRD), 13% had 
severe renal failure with an estimated glomerular filtration rate (eGFR) <30 
mL/min/1.73m2, and 14% had moderate renal failure with eGFR<50 
mL/min/1.73m2(7). Factors associated with evolution to ESRD included baseline 
renal function, baseline proteinuria >1 or 1.5 g/day, macroscopic hematuria, 
hypertension, and proteinuria ≥1 g/day during follow-up (7-9). In a study from 
Southern European population, hematuria at disease onset, renal involvement during 
the course of the disease, anemia at the time of diagnosis and onset of the disease 
in summer were more common in patients with renal sequelae (10). On renal biopsy, 
degree of interstitial fibrosis, sclerotic glomeruli and fibrinoid necrosis were also 
associated with a poor renal prognosis (7). 
 Treatment has been poorly investigated in adults. Management of IgAV is 
often symptomatic because of the frequent benign course of the disease with 
spontaneous remission. However, in case of severe involvement with organ and/or 
life-threatening complications, corticosteroids (CS) or/and immunosuppressive drugs 
are often initiated. Pillebout et al. conducted the only prospective, multicenter, open 
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label trial in adults, comparing CS alone versus CS plus cyclophosphamide (CYC) in 
patients with severe IgAV (11). Fifty-four patients with biopsy-proven IgAV and 
severe manifestations, including proliferative glomerulonephritis and/or severe 
gastrointestinal manifestations, were included. At 12 months, no difference was 
found between the 2 groups in terms of remission rate, renal outcomes and adverse 
events. However, overall survival at 12 months tended to be better in the CS plus 
CYC group compared to CS alone [96% (95% CI 89–100) vs. 79% (95% CI 64–93); 
P=0.08). Hence, the optimal therapeutic strategy has yet to be defined in adults.  
 To better define the clinical spectrum and the efficacy of treatments in IgAV in 
adults, a nationwide survey was initiated in France in 2013. Data from the 260 cases 
of IgAV in adults included in the IGAVAS survey are reported here. 
 
Patients and methods  
Patients 
This multicentric retrospective survey was conducted in French university and 
general hospitals in departments of Internal Medicine, Nephrology, Dermatology and 
Rheumatology. The study was performed in accordance with ethical standards of the 
Helsinki Declaration, and was approved by Institutional Review Board. The inclusion 
criteria for the study were (1) age >18 years old, (2) IgA vasculitis, and (3) diagnosis 
of IgAV between January 1990 and January 2015. Patients were considered to have 
IgAV if they presented (1) purpura, (2) histologically proven small vessels vasculitis, 
(3) IgA histologically proven deposits and (4) involvement of at least one organ 
among kidney, joint, or intestinal tract. Exclusion criteria were IgAV associated with a 
diagnosis of cancer in the 5 previous years before vasculitis onset.  
Clinical and biologic data 
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Clinical and biologic data were recorded for each patient at the time of the initial 
evaluation, during follow-up (6 and 12 months after initial evaluation), and at the end 
of follow-up, by the practitioners in charge of the patients with the use of a 
standardized form. Laboratory assessment included in particular the determination of 
serum creatinine level and a urinalysis to screen for hematuria and a 24-hour urine 
protein examination. Renal failure was defined as an eGFR<60 mL/min/1.73m2, 
assessed with the Modified Diet in Renal Disease equation (12). Proteinuria was 
defined as 24-hour urine protein excretion >0.5 g/day, and hematuria was defined as 
>10 red cells/mm3 in the urine considered as macroscopic if >1500 red cells/mm3. 
Elevated IgA levels was defined as IgA >3.5 g/L. 
Histological data 
Histological data (skin and renal biopsies) were recorded at the time of diagnosis. 
Pathology reports for renal biopsies were examined by two independent 
nephrologists (ET and EP) blinded to the clinical features. According to the presence 
of focal or diffuse distribution, extracapillary proliferation, number of glomeruli 
involved, interstitial fibrosis, proportions of glomeruli involved by crescents, fibrinoid 
necrosis and global sclerosis, all biopsies were classified according to the 
classification previously described by Pillebout et al. (7). 
Response to therapy 
The response to therapy of IgAV was defined by analysing the course of the following 
main clinical signs: skin involvement (purpura), articular manifestations (arthralgia 
and/or arthritis), gastrointestinal symptoms and renal involvement (normalization or 
improvement of eGFR, proteinuria and hematuria). Response were evaluated by 2 
independent physicians (AAV and BT) blinded to the treatment received. A complete 
response was defined as an improvement in all baseline clinical manifestations and 
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in case of renal involvement by a proteinuria <0.5 g/d, the disappearance of 
hematuriaand no decrease of the glomerular filtration rate (GFR) greater than 20% 
from baseline. A partial response was defined as an improvement in at least one-half 
of the baseline clinical manifestations, and in case of renal involvement as an 
improvement of proteinuria > 50% of the baseline value, disappearance or not of 
hematuria, and no decrease of the GFR greater than 20% from baseline.  All others 
patients were classified as non-responder. Relapse was defined as the reappearance 
of clinical signs of vasculitis, occurring after a period free of symptoms of at least a 
one month. Minor relapse was defined by increase of prednisone no greater than 20 
mg/day and major relapse by addition of immunosuppressive drug or increase of 
prednisone greater than 20 mg/day. Others patients were considered as having no 
relapse. 
Statistical analysis 
Descriptive statistics included the mean (SD) or median [Q1; Q3] when appropriate 
for continuous variables, and frequency (percentage) for categorical variables. 
Univariate analysis included the Chi2 or Fisher exact test as appropriate to compare 
categorical variables and the nonparametric Mann-Whitney test to compare 
continuous variables. To evaluate efficacy of therapeutic regimens, we performed a 
multivariable logistic regression model to assess factors independently associated 
with response to therapy. All important factors in the literature as well as those 
associated with being treated or with response to therapy in univariate analysis were 
included in the final model. Correlated variables were not all entered in the model to 
avoid the risk of collinearity. To account for a potential indication bias (ie, patients 
treated with corticoids or CYC may be more severe than those treated with colchicine 
only), we also estimated a propensity score corresponding to the probability of being 
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treated with corticosteroids or CYC rather than Colchicine according to patients’ 
characteristics (age, gender, gastro-intestinal bleeding, creatininemia, proteinuria, 
necrotic purpura) using a logistic regression model (13, 14). We performed an 
evaluation of the distributions of propensity scores by treatment groups checking for 
sizeable overlap among the treatment groups (ie, it is not possible to use a 
propensity score when the two groups are too different, this is why, it is important to 
check whether the two groups overlap). There are several ways to use the propensity 
score in analysis including adjustment on propensity score as a covariate in the 
model, matching of individuals treated and not treated on their propensity score and 
inverse probability weighting by propensity score. The 2 preferred methods are 
matching and weighting (15). However, it is not always possible to use matching as 
participants not matched (ie, patients treated and not treated for which the propensity 
score is not the same) do not participate in analysis. In this study, we used both 
adjustment on propensity score and inverse probability weighting on propensity score 
in logistic regression models to assess whether a treatment by corticosteroids or 
CYC was associated with a better response compared to colchicine and to assess 
whether a treatment by CYC was associated with a better response compared to 
corticosteroid alone. Because inverse probability weighting analysis may be sensitive 
to extreme propensity scores (13, 14), we did a sensitivity analysis excluding the 5% 
of patients with the lowest propensity scores. 
Adjusted Odds ratios for all covariates in the model without propensity score are 
showed in the Supplemental Material Table 1. 
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Results 
Of the 304 patients assessed for eligibility in the IGAVAS survey, 260 patients were 
included. Forty-four patients were excluded because of absence of proven IgA 
deposits (n=27), absence of proven vasculitis (n=4), concomitant cancer (n=6) or 
missing data (n=7).  
Clinical and biological patient characteristics 
The characteristics of the 260 patients with IgAV are shown in Table 1. The mean 
age at diagnosis was 50.1±18 years and 164 patients (63%) were male. Clinical 
manifestations included constitutional symptoms in 87 patients (33%), cutaneous 
involvement with purpura in all patients (100%), arthralgia/arthritis in 159 patients 
(61%), renal involvement in 182 patients (70%) and gastrointestinal involvement in 
137 patients (53%). Thirty percent of the patients showed renal failure (eGFR<60 
ml/min/1.73m2) at baseline. Patients with renal involvement displayed a 90 
mL/min/1.73m2 [66; 110] median eGFR, a 1.5 g/day median proteinuria level [0.6; 3], 
and 88% presented hematuria. The median serum IgA level was 3.6 g/L [2.7; 4.8] 
and 85/159 patients (53%) presented elevated IgA levels. 
Anti-neutrophil cytoplasmic antibodies (ANCA) were detected in 9/225 patients (4%) 
and antinuclear antibodies (ANA) in 33/231 patients (14%), both without any 
specificity (data not shown). 
Histological features 
The characteristics of skin and renal biopsies performed in the patients are 
summarized in Table 2. Skin biopsy was performed in 222 patients (85%), and renal 
biopsy in 144 of the 182 patients with kidney involvement (79%). The skin biopsy 
demonstrated leukocytoclastic vasculitis in 205 patients (92%). Direct immuno-
fluorescence revealed IgA and complement deposition in blood vessels of the upper 
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dermis in 174/216 (81%) and 47/222 (21%) patients. In 6 skin biopsies, direct 
immuno-fluorescence was not performed. The renal biopsy demonstrated IgA 
mesangial deposits in 142/144 patients (99%) and extracapillary proliferation in 
59/143 patients (41%). Of the pathology reports that were independently reviewed 
(n=67), majority of patients were classified as class 2 in 33/67 (49%), i.e. a focal and 
segmental glomerulonephritis with segmental endo- and extracapillary proliferation 
involving less than 50% of the glomeruli, and class 3a in 18/67 (27%), i.e. an 
endocapillary proliferative glomerulonephritis with moderate endocapillary 
proliferative lesions. 
Treatments used 
Treatments used were colchicine only in 27 patients, corticosteroids alone in 122 
patients, and corticosteroids in combination with cyclophosphamide in 35 patients. 
Ten patients received various therapies, including dapsone in 4 cases, rituximab in 2 
cases, mycophenolate mofetil in 2 cases and hydroxychloroquine in 2 cases. Sixty-
six patients did not receive a specific treatment. 
Baseline characteristics of the 250 patients according to the treatment used (except 
the 10 patients with various treatments) are shown in Table 3. Compared to patients 
who received no treatment or who received only colchicine, patients treated with CS 
or CS plus CYC were more frequently male (P=0.004), presented at baseline more 
frequently with necrotic purpura (P=0.006), renal involvement (P=0.0001), higher 
levels of proteinuria (P<0.0001) and hematuria (P=0.0005), more frequent endo- and 
extracapillary proliferation (P<0.0001), and more frequent and severe gastrointestinal 
tract involvement (P<0.0001). These factors, as well as significant factors previously 
described in the literature were included in the multivariable logistic regression model 
and the estimation of the propensity score. 
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Effect of therapeutic regimen on response to treatment and outcome  
Of the 260 patients, 132 patients received either colchicine, CS or CS plus CYC, and 
had a follow-up >6 months. Follow-up data were missing for 5 patients, who did not 
differ from the remaining patients (data not shown). Finally, 127 patients were 
analyzed. Patients characteristics according to the achievement of partial or 
complete response in comparison with those with no response within the first 12 
months of follow-up are summarized in Table 4.  
In univariate analysis, no characteristic or treatment was significantly associated with 
the achievement of partial or complete response. Partial or complete response was 
obtained in 64/80 patients (80%) treated with CS, 23/30 patients (77%) treated with 
CS plus CYC, and 10/17 (59%) treated with colchicine (P=0.17).  
Among the 66 patients who did not receive any treatment, 34 could be analysed 
because they were followed-up for at least 6 months. In univariate analysis 85% 
(n=29/34) presented spontaneous remission at month 6 and/or 12. 
Although patients were not comparable in each treatment group, Supplemental 
Material Table 2 shows that cutaneous and renal manifestations persisted between 
month 6 to 12 in 7 to 41% and 10 to 40% according to treatments used, respectively. 
We then evaluated the efficacy of treatments after adjusting for confounding factors. 
The results of the multivariable logistic regression model, adjusted for gender, 
creatinine, proteinuria, digestive bleeding and necrotic purpura. The multivariable 
propensity score adjusted logistic regression model, and the inverse probability 
weighting on propensity score, with or without sensitivity analysis excluding outliers 
are indicated in Figures 1 and 2. 
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Treatment with CS or CS plus CYC were more effective than colchicine in achieving 
a partial or complete response using multivariable logistic regression model [OR 
(95% CI) 3.68 (1.10-12.33), P=0.03], the multivariable propensity score adjusted 
logistic regression model [OR (95% CI) 3.58 (1.07-11.94), P=0.04] and inverse 
probability weighting on propensity score [OR (95% CI) 3.75 (1.28-10.99), P=0.02] 
(Figure 1).  
We also compared the efficacy of CS plus CYC versus CS (Figure 2) and found 
discordant results according to the method used. The use of multivariable logistic 
regression model [OR (95% CI) 0.88 (0.29-2.67), P=0.82] and the multivariable 
propensity score adjusted logistic regression model [OR (95% CI) 0.90 (0.29-2.78), 
P=0.86] did not demonstrate any difference between the 2 therapeutic strategies in 
achieving a partial or complete response. In contrast, the use of inverse probability 
weighting on propensity score with [OR (95% CI) 1.79 (1.00-3.20), P=0.049] or 
without sensitivity analysis excluding outliers [OR (95% CI) 2.33 (1.29-4.18), 
P=0.005] showed that treatment with CS plus CYC were more effective than CS in 
achieving a partial of complete response.  
Follow-up of patients  
After a median follow-up of 17.2 months [9.1-38.3] corresponding to 593 patient-
years, 8 patients died, including 3 deaths directly related to IgAV (2 mesenteric 
ischemia and 1 multivisceral failure). Eight patients experienced end stage renal 
failure treated by renal transplantation (n=2) or dialysis (n=6). Among patients who 
received a treatment, data concerning relapse during the first 12 months after 
treatment were available in 107 patients and showed 15 minor relapse (14%) and 9 
(8%) a major relapse. Among untreated patients, data concerning relapse during the 
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first 12 months of follow-up were available in 10 patients and showed one minor 
relapse (10%). 
 
Discussion 
It has been clearly reported that the clinical presentation and prognosis of 
adults IgAV differs from that of children. Because randomized controlled trials are 
lacking in the literature, evaluation of efficacy of the different therapeutic regimens, 
which is mandatory to improve the management of IgAV patients, was a main goal of 
the IGAVAS survey. To better define the clinical spectrum and the therapeutic 
management of IgAV, we analyzed the data from 260 patients included in the French 
multicenter and transdisciplinary IGAVAS survey, which constitutes the largest series 
of adults reported so far in the literature.  
Patients in our study were comparable to those previously described by others 
(16-20). They were predominantly male, while mean age was 50 years compared to 
32 to 44 years in previous series (16-20) and 48 years in a northwestern Spanish 
epidemiologic study (5). The incidence of cutaneous, articular and gastrointestinal 
tract involvement were also comparable with those described in others series, except 
for the renal involvement which was more prevalent in our series (70% versus 30 to 
60% in others series) (16-20). This finding is probably related to the high rate of 
patients that were included by nephrologists in our survey. Considering laboratory 
findings, the prevalence of increased serum IgA levels (53%) was slightly more 
important than in other series (31 to 52%) (16-20). 
Treatment of IgAV is often symptomatic because the disease course is usually 
benign. In more severe forms, some reports dealt with the use of CS and 
immunosuppressive agents (21), but randomized controlled trials are lacking in adult 
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IgAV. Corticosteroids are effective on arthralgia and abdominal pain and there is a 
considerable controversy on the benefit of corticosteroids to treat renal involvement 
and prevent evolution to end-stage renal disease especially in both pediatric and 
adult population (22-25). In adult IgAV with severe nephritis, Ren et al. suggested 
that mycophenolate mofetil could be useful for inducing remission and as steroid-
sparing agent, but long-term effect on renal function is not known (26). By analogy 
with severe autoimmune diseases, CYC has been used in patients with organ- or life-
threatening IgAV manifestations. Pillebout et al. compared CS with or without CYC in 
severe adults IgAV, in a prospective open-label trial (11). Fifty-four patients with 
biopsy proven IgAV and severe manifestations were included and randomized to 
receive CS alone or CS plus CYC. At 6 months, no difference was found between the 
2 groups for the primary endpoint, i.e. the achievement of complete disease 
remission defined as zero on the Birmingham Vasculitis Activity Score (BVAS) (27), 
with no persistent or new clinical and/or biological vasculitis manifestation. The 
secondary endpoints, i.e. renal outcome, deaths, and adverse events, also did not 
differ at 12 months. However, only 54 patients of the 200 initially planned were 
included, explaining why data should be interpreted with caution. In addition, overall 
survival at 12 months tended to be better using CYC, with an overall survival of 96% 
in the CS plus CYC arm compared to 79% with CS alone (P=0.08), explaining why 
the interest of CYC remains controversial. Recommendations from the Kidney 
Disease Improving Global Outcomes (KDIGO) suggest that IgAV-related nephritis in 
adults should be treated similary as children and should not be used except for CYC 
in crescentic glomerulonephritis (crescents in >50 % of the glomeruli) with nephrotic 
syndrome or rapid degradation of eGFR (28). 
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The descriptive analysis of real-life patients may also provide interesting findings on 
the efficacy of the different therapeutic regimen. In this study, we used several 
complementary approaches to compare treatment efficacy. First, we did a 
multivariable analysis taking into account potential confounding factors which was not 
frequently done in previous studies because of their limited sample size. We also 
used a propensity score to take into account a potential indication bias as patients 
treated with CS plus CYC may be more severe at baseline than those treated with 
CS alone or colchicine (15). We took the propensity score into account in analysis 
with both adjustment and ponderation by inverse variance. All approaches showed 
concordant results for the comparison between CS or CS plus CYC versus 
colchicine. Futhermore, our cohort may have a cohort biased toward more severe 
disease and the prevalence and course of less serious disease cannot be interpreted 
to the same extent as more serious disease. 
However, this was not the case for the comparison between CS alone and CS plus 
CYC showing contradictory results according to the statistical methods used. Indeed, 
multivariable logistic regression model and multivariable propensity score adjusted 
logistic regression model did not demonstrate any difference between the 2 
therapeutic strategies. In contrast, the use of inverse probability weighting on 
propensity score with or without sensitivity analysis showed that CS plus CYC were 
more effective than CS alone in achieving a partial of complete response. Propensity 
score weighting is frequently recommended but could be sensitive to outliers, so no 
definitive conclusion can be taken for this comparison (13, 14). In addition, we cannot 
exclude bias related to unknown confounders not taken into account in the propensity 
score. 
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These conflicting results reflect that, besides limitations related to the retrospective 
design and possibly to insufficient power to detect any difference, no firm conclusion 
can be drawn regarding the comparison between CS alone and CS plus CYC. In 
addition, the low number of patients receiving colchicine alone or CS plus CYC, as 
well as the number of non-responder patients, may have limited the power of the 
study. However, given potential adverse events related to the adjunction of CYC in 
this condition, CS alone seems appears to be reasonable in first-line in patients with 
systemic IgAV, except in very severe presentations in which decisions should be 
made individually. 
 In conclusion, this series constitutes the largest series reported so far in the 
literature of adults IgAV. It provides interesting data on clinical and histological 
presentation and therapeutic efficacy, showing that CS alone appears to be a 
reasonable first-line therapy in patients with systemic IgAV, while the use of CYC 
remains controversial.  
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Figure legends : 
Figure 1: Efficacy of Corticosteroids or Cyclophosphamide versus Colchicine  
Figure 2: Efficacy of Corticosteroids plus Cyclophosphamide versus 
Corticosteroids alone  
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Tables 
Table 1. Main characteristics at baseline of the 260 patients with IgAV included 
in the IGAVAS survey. 
Baseline characteristics  
  
Epidemiologicalfeatures  
Age at diagnosis, y, mean ±SD 50.1 ± 18.6 
Male, n (%) 164 (63) 
  
Clinical manifestations  
Constitutionalsymptoms, n (%) 87/260 (33) 
Fever 39/260  (15) 
Asthenia 54/260  (21) 
Weightloss 22/260  (8) 
Skin, n (%) 260/260  (100) 
Purpura 260/260  (100) 
Lowerlimb 260/260  (100) 
Upperlimb 93/260  (36) 
   Abdomen 63/260  (24) 
   Face 8/260  (3) 
Necrosis 67/260  (25) 
Hemorrhagic blisters 22/260  (8) 
Joints, n (%) 159/260  (61) 
Arthralgia 159/160  (100) 
Arthritis 26/160  (16) 
Myalgia 10/160  (6) 
Gastrointestinal tract, n (%) 137/260  (53) 
Abdominal pain 135/137  (99) 
Bleeding 43/137  (31) 
Diarrhea 36/137  (26) 
Nausea 26/137  (19) 
Ileus 13/137  (9) 
Kidney, n (%) 182/260 (70) 
Oedema 49/182 (27) 
High blood pressure 40/182 (22) 
Macroscopic hematuria 18/182 (10) 
Others, n (%) 13/260  (5) 
Peripheralneuropathy 4/260   (2) 
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Orchiepidymitis 4/260   (2) 
Cardiopathy 2/260   (1) 
Intraalveolarhemorrhage 1/260  (0.5) 
  
Biologicfeatures  
Serum IgA level, g/L, median, [Q1; Q3] 3.6[2,7; 4,8] 
Elevated serumIgA, n (%) 85/159 (53) 
Serum creatinine level, µmol/L, median, [Q1; Q3] 77 [65; 99] 
eGFR, mL/min/1.73m
2
, median, [Q1; Q3] 90 [66; 110] 
eGFR<60 mL/min/1.73m
2
, n (%) 55/181 (30) 
Albumin, g/L median, [Q1; Q3] 33[27; 38] 
Haematuria, n (%) 153/174 (88) 
Proteinuria, g/day, median, [Q1; Q3] 1.5 [0.6; 3] 
CRP, mg/L, median, [Q1; Q3] 27 [8; 60] 
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Table 2. Histological features of the patients with IgAV included in the IGAVAS 
survey. 
Histological features  
  
Skin biopsy, n (%) 222/260 (85) 
Leukocytoclastic vasculitis 205/222 (92) 
IgAdeposits 174/216 (81) 
C3 deposits 47/222 (21) 
Fibrinoid necrosis 59/222 (27) 
  
Renalbiopsy 144/182 (79) 
IgA mesangial deposits, n (%) 142/144 (99) 
Extracapillaryproliferation, n (%) 59/144 (41) 
Fibrinoid necrosis, n (%) 46/144 (32) 
Glomerularsclerosis, n (%) 47/144 (33) 
% of glomerular sclerosis, median [Q1; Q3] 11 [7; 20] 
% of interstitial fibrosis, median [Q1; Q3] 15 [10; 21] 
Tubulointerstitial nephritis, n (%) 44/144 (31) 
Classification, n (%)  
Class 1 2/67 (3) 
Class 2 33/67 (49) 
Class 3a 18/67 (27) 
Class 3b 9/67 (13) 
Class 4 4/67 (6) 
Class 5 1/67 (2) 
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Table 3. Characteristics of the patients according to treatment received 
 
Characteristics 
CS + CYC  
n=35 
CS 
n=122 
Colchicine 
only 
n=27 
No therapy 
n=66 
 
P 
      
Age, mean (SD) 47 (18) 51 (20) 45 (16) 51 (18) 0.36 
Gender, n (%) 
     Men 
     Women 
 
31 (89) 
4 (11) 
 
76 (62) 
45 (38) 
 
15 (56) 
12 (44) 
 
35 (53) 
31 (47) 
0.004 
Skin involvement, n (%) 
     Necrotic purpura 
     Fibrinoid necrosis at biopsy 
35 (100) 
17 (49) 
9 (26) 
122 (100) 
30 (25) 
33 (27) 
27 (100) 
5 (19) 
4 (15) 
66 (100) 
12 (18) 
11 (17) 
- 
0.006 
0.28 
Joint involvement, n (%) 23 (66) 79 (65) 16 (59) 32 (48) 0.15 
Renal involvement, n (%) 
     Proteinuria >1 g/d, n (%) 
     Proteinuria >3 g/d, n (%) 
     Hematuria, n (%) 
     Creatinine, median [Q1; Q3] 
eGFR, median [Q1; Q3] 
Biopsy performed, n (%) 
Endocapillary GN, n (%) 
Extracapillary GN, n (%) 
30 (86) 
24 (69) 
13 (37) 
27 (77) 
80 (70-117) 
90 (50-112) 
29 (83) 
18 (62) 
14 (48) 
93 (76) 
53 (43) 
24 (20) 
79 (65) 
80 (66-111) 
90 (61-108) 
69 (57) 
33 (48) 
35 (51) 
11 (41) 
4 (15) 
1 (4) 
9 (33) 
75 (66-85) 
96 (87-105) 
8 (30) 
3 (37) 
0 (0) 
39 (59) 
17 (26) 
5 (7) 
31 (47) 
71 (62-86) 
98 (80-111) 
29 (44) 
9 (31) 
5 (17) 
0.0001 
<0.0001 
0.0004 
0.0005 
0.02 
0.23 
<0.0001 
GI involvement, n (%) 
     Ileus 
     Bleeding  
     Surgical abdomen 
26 (74) 
3 (9) 
14 (40) 
3 (9) 
75 (61) 
8 (7) 
23 (19) 
2 (2) 
7 (26) 
0 (0) 
1 (4) 
0 (0) 
21 (32) 
2 (3) 
2 (3) 
0 (0) 
<0.0001 
0.38* 
<0.0001 
0.054* 
      
CS : corticosteroids ; CYC :cyclophosphamide ; GN :glomerulonephritis, GI :gastrointestinal  
*Fisher exact test 
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Table 4. Characteristics of patients according to the achievement of partial or 
complete response in comparison with those without any response.  
 
Characteristics 
Response  
n=97 
No response  
n=30 
 
p 
    
Age, mean (SD) 49 (19) 48 (17) 0.72 
Gender, n (%) 
     Men 
     Women 
 
61 (63) 
36 (37) 
 
23 (77) 
7 (23) 
0.16 
Skin involvement, n (%) 
     Necrotic purpura 
     Fibrinoid necrosis at biopsy 
97 (100) 
30 (31) 
25 (26) 
30 (100) 
9 (30) 
8 (27) 
NA 
0.92 
0.92 
Joint involvement, n (%) 65 (67) 16 (53) 0.17 
Renal involvement, n (%) 
     Proteinuria >1 g/d, n (%) 
     Proteinuria >3 g/d, n (%) 
     Hematuria, n (%) 
     Creatinin, median [Q1; Q3] 
eGFR, median [Q1; Q3] 
Biopsy performed, n (%) 
Endocapillary GN, n (%) 
Extracapillary GN, n (%) 
69 (71) 
46 (47) 
22 (23) 
58 (60) 
76 (67-104) 
95 (65-111) 
59 (61) 
31 (53) 
30 (51) 
21 (70) 
16 (53) 
9 (30) 
17 (57) 
88 (78-110) 
86 (57-96) 
19 (63) 
11 (58) 
8 (42) 
0.90 
0.57 
0.41 
0.76 
0.31 
0.14 
0.80 
GI involvement, n (%) 
     Ileus 
     Bleeding  
     Surgical abdomen 
55 (57) 
4 (4) 
28 (29) 
2 (2) 
15 (50) 
1 (3) 
4 (13) 
1 (3) 
0.52 
1* 
0.09 
0.56* 
First line treatment, n (%) 
     CS (n=80) 
     CS + CYC (n=30) 
     Colchicine (n=17) 
 
64 (66) 
23 (24) 
10 (10) 
 
16 (53) 
7 (23) 
7 (23) 
0.17 
    
CS : corticosteroids ; CYC :cyclophosphamide ; GN :glomerulonephritis, GI :gastrointestinal 
* Fisher exact test. 
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